Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy
- 20 May 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15), 2505-2511
- https://doi.org/10.1200/jco.2007.11.9214
Abstract
Purpose: Marrow failure in some patients with myelodysplastic syndrome (MDS) responds to immunosuppressive treatment (IST), but long-term outcome after IST has not been described. We evaluated patients with MDS treated with IST at our institution to determine their clinical course compared with a comparable supportive care only group. Patients and Methods: One hundred twenty-nine patients with MDS received IST with a median follow-up of 3.0 years (range, 0.03 to 11.3 years), using antithymocyte globulin (ATG) or cyclosporine (CsA) in combination or singly. Variables affecting response and survival were studied and outcomes were compared with those of 816 patients with MDS reported to the International Myelodysplasia Risk Analysis Workshop (IMRAW) who received only supportive care. Results: Thirty-nine (30%) of 129 patients receiving IST responded either completely or partially: 18 (24%) of 74 patients responded to ATG, 20 (48%) of 42 patients responded to ATG plus CsA, and one (8%) of 13 patients responded to CsA. Thirty-one percent (12 of 39) of the responses were complete, resulting in transfusion independence and near-normal blood counts. In multivariate analysis, younger age was the most significant factor favoring response to therapy. Other favorable factors affecting response were HLA-DR15 positivity and combination ATG plus CsA treatment (P = .001 and P = .048, respectively). In multivariate analysis of the combined IMRAW and IST cohorts, younger age, treatment with IST, and intermediate or low International Prognostic Scoring System score significantly favored survival. Conclusion: IST produced significant improvement in the pancytopenia of a substantial proportion of patients with MDS and was associated with improved overall and progression-free survival, especially in younger individuals with lower-risk disease.Keywords
This publication has 30 references indexed in Scilit:
- Immunologic mechanisms and treatment of myelodysplastic syndromesPublished by Cambridge University Press (CUP) ,2005
- Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSFBlood, 2005
- Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantationTransplantation and Cellular Therapy, 2005
- Efficacy of Lenalidomide in Myelodysplastic SyndromesNew England Journal of Medicine, 2005
- DNA methyltransferase inhibitors in myelodysplastic syndromeBest Practice & Research Clinical Haematology, 2004
- Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemiaBlood, 2004
- The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesLeukemia Research, 2004
- Myelodysplastic SyndromesHematology-American Society Hematology Education Program, 2004
- Current challenges in therapy of myelodysplastic syndromesCurrent Opinion in Hematology, 2003
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002